<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neurosurgery Blog &#187; complications</title>
	<atom:link href="http://www.neurosurgery-blog.com/archives/category/complications/feed" rel="self" type="application/rss+xml" />
	<link>http://www.neurosurgery-blog.com</link>
	<description>Daily bibliographic and video review of the Neurosurgery Department. La Fe University Hospital. Valencia, Spain</description>
	<lastBuildDate>Thu, 09 Feb 2012 23:00:45 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Patient comorbidity score predicting the incidence of perioperative complications: assessing the impact of comorbidities on complications in spine surgery</title>
		<link>http://www.neurosurgery-blog.com/archives/3740</link>
		<comments>http://www.neurosurgery-blog.com/archives/3740#comments</comments>
		<pubDate>Thu, 26 Jan 2012 23:00:59 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Outcome]]></category>
		<category><![CDATA[Spine]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[comorbidity]]></category>
		<category><![CDATA[complication]]></category>
		<category><![CDATA[Spine surgery]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/archives/3740</guid>
		<description><![CDATA[J Neurosurg Spine 16:37–43, 2012. DOI: 10.3171/2011.9.SPINE11283
Present attempts to control health care costs focus on reducing the incidence of complications and hospital-acquired conditions (HACs). One approach uses restriction or elimination of hospital payments for HACs. Present approaches assume that all HACs are created equal and that payment restrictions should be applied uniformly. Patient factors, and [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/MI-AP1.jpg"><img class="alignleft size-thumbnail wp-image-3748" title="MI-AP" src="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/MI-AP1-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg Spine 16:37–43, 2012. DOI: 10.3171/2011.9.SPINE11283</strong></p>
<p style="text-align: justify;">Present attempts to control health care costs focus on reducing the incidence of complications and hospital-acquired conditions (HACs). One approach uses restriction or elimination of hospital payments for HACs. Present approaches assume that all HACs are created equal and that payment restrictions should be applied uniformly. Patient factors, and especially patient comorbidities, likely impact complication incidence. The relationship of patient comorbidities and complication incidence in spine surgery has not been prospectively reported.</p>
<p style="text-align: justify;">METHODS: The authors conducted a prospective assessment of complications in spine surgery during a 6-month period; an independent auditor and a validated definition of perioperative complications were used. Initial demographics captured relevant patient comorbidities. The authors constructed a model of relative risk assessment based on the presence of a variety of comorbidities. They examined the impact of specific comorbidities and the cumulative effect of multiple comorbidities on complication incidence.</p>
<p style="text-align: justify;">RESULTS: Two hundred forty-nine patients undergoing 259 procedures at a tertiary care facility were evaluated during the 6-month duration of the study. Eighty percent of the patients underwent fusion procedures. One hundred thirty patients (52.2%) experienced at least 1 complication, with major complications occurring in 21.4% and minor complications in 46.4% of the cohort. Major complications doubled the median duration of hospital stay, from 6 to 12 days in cervical spine patients and from 7 to 14 days in thoracolumbar spine patients. At least 1 comorbid condition was present in 86% of the patients. An increasing number of comorbidities strongly correlated with increased risk of major, minor, and any complications (p = 0.017, p &lt; 0.0001, and p &lt; 0.0001, respectively). Patient factors correlating with increased risk of specific complications included systemic malignancy and cardiac conditions other than hypertension.</p>
<p style="text-align: justify;">CONCLUSIONS: Comorbidities significantly increase the risk of perioperative complications. An increasing number of comorbidities in an individual patient significantly increases the risk of a perioperative adverse event. Patient factors significantly impact the relative risk of HACs and perioperative complications.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3740/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Perioperative surgical complications of transforaminal lumbar interbody fusion: a single-center experience</title>
		<link>http://www.neurosurgery-blog.com/archives/3713</link>
		<comments>http://www.neurosurgery-blog.com/archives/3713#comments</comments>
		<pubDate>Sun, 22 Jan 2012 23:00:56 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Spine]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[complication]]></category>
		<category><![CDATA[Durotomy]]></category>
		<category><![CDATA[Infection]]></category>
		<category><![CDATA[transforaminal lumbar interbody fusion]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3713</guid>
		<description><![CDATA[J Neurosurg Spine 16:44–50, 2012. DOI: 10.3171/2011.9.SPINE11373
Since its original description in 1982, transforaminal lumbar interbody fusion (TLIF) has grown in popularity as a means for achieving circumferential fusion. The authors sought to define the perioperative complication rates of the TLIF procedure at a large academic medical center.
Methods. For all eligible patients from a consecutive series [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/tlif.jpg"><img class="alignleft size-thumbnail wp-image-3718" title="tlif" src="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/tlif-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg Spine 16:44–50, 2012. DOI: 10.3171/2011.9.SPINE11373</strong></p>
<p style="text-align: justify;">Since its original description in 1982, transforaminal lumbar interbody fusion (TLIF) has grown in popularity as a means for achieving circumferential fusion. The authors sought to define the perioperative complication rates of the TLIF procedure at a large academic medical center.</p>
<p style="text-align: justify;">Methods. For all eligible patients from a consecutive series of 531 TLIF procedures, the institution’s complication database and the medical record were reviewed to identify complications. Medical, nonprocedure-related complications such as myocardial infarction and pulmonary embolism were excluded due to inconsistency in the recording of these complications in the database. Rates were calculated for each type of complication, and subgroup analysis was performed to investigate the effect of previous lumbar surgery, and of multilevel versus single-level interbody fusion on complication rates. Odds ratios were calculated and evaluated using chi-square analysis.</p>
<p style="text-align: justify;">Results. Five hundred thirty-one patients underwent a TLIF procedure during the study period. Two hundred forty-four patients (46%) had undergone a previous lumbar operation. Interbody fusion was performed at 1 level in 317 patients, at 2 levels in 188 patients, at 3 levels in 24 patients, and at 4 levels in 2 patients. One hundred thirty-five patients (25.4%) had at least one procedure-related complication. The most common complications were durotomy (14.3% of patients) and infection (3.8% of patients). Symptomatic screw misplacement (2.1% of patients) and interbody cage migration (1.8% of patients) were less common complications. The overall complication rate was greater in those patients who had undergone a previous operation (OR 1.75, 95% CI 1.18–2.59; p &lt; 0.01) and in those who had multilevel surgery (OR 1.54, 95 % CI 1.04–2.28; p = 0.03), and the incidence of durotomy was higher in patients who had a previous operation (OR 1.75, 95% CI 1.07–2.87; p = 0.03). These differences were statistically significant. Durotomy also occurred more frequently in patients who had multilevel interbody fusion (OR 1.49, 95% CI 0.92–2.43; p = 0.13). A trend toward higher infection rates in those patients who underwent multilevel interbody fusion was observed (OR 1.5, 95% CI 0.62–3.68; p = 0.49), but this was not statistically significant. Infection rates did not differ between revision and first-time surgeries.</p>
<p style="text-align: justify;">Conclusions. Transforaminal lumbar interbody fusion has gained widespread popularity as a procedure for achieving arthrodesis in the lumbar spine. Complications occurred more often in patients undergoing revision surgery or multilevel interbody fusion. Durotomy and infection were the most common complications in this series.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3713/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neuroembolization may expose patients to radiation doses previously linked to tumor induction</title>
		<link>http://www.neurosurgery-blog.com/archives/3617</link>
		<comments>http://www.neurosurgery-blog.com/archives/3617#comments</comments>
		<pubDate>Mon, 02 Jan 2012 23:00:27 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Vascular]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[neurorradiology]]></category>
		<category><![CDATA[Coiling]]></category>
		<category><![CDATA[Neuroembolization]]></category>
		<category><![CDATA[Radiation doses]]></category>
		<category><![CDATA[Radiation-induced alopecia]]></category>
		<category><![CDATA[Radiation-induced cancers]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3617</guid>
		<description><![CDATA[Acta Neurochir (2012) 154:33–41. DOI 10.1007/s00701-011-1209-9
Epidemiological studies indicate a link between low-dose irradiation (&#60;10,000 mGy) to the head and the local occurrence of tumors after decades of delay. Comparable radiation doses can be reached during neuroendovascular procedures (NEP), but the incidence of similar exposures has not been completely delineated. We compared the levels of radiation [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Neuroembolization-may-expose-patients.jpg"><img class="alignleft size-thumbnail wp-image-3621" title="Neuroembolization may expose patients" src="http://www.neurosurgery-blog.com/wp-content/uploads/2012/01/Neuroembolization-may-expose-patients-150x150.jpg" alt="" width="150" height="150" /></a>Acta Neurochir (2012) 154:33–41. DOI 10.1007/s00701-011-1209-9</strong></p>
<p style="text-align: justify;">Epidemiological studies indicate a link between low-dose irradiation (&lt;10,000 mGy) to the head and the local occurrence of tumors after decades of delay. Comparable radiation doses can be reached during neuroendovascular procedures (NEP), but the incidence of similar exposures has not been completely delineated. We compared the levels of radiation to the head measured during NEP to those reported for patients developing radiation-induced cancers.</p>
<p style="text-align: justify;">Methods In our prospective study we determined the cumulative maximum entrance skin doses (MESD) and the incidence of epilation in 107 consecutive patients submitted to NEP between 2003 and 2007. We also extensively searched the literature and compared our results with the data we found.</p>
<p style="text-align: justify;">Results The cumulative MESD due to NEP was above 3,000 mGy (range 3,101–5,421 mGy) in 18 patients. In 22 we observed partial epilation within 10 weeks from the initial NEP. Sixty cases of epilation after NEP have been previously reported in the literature. The average of the reported MESD was 4,241 mGy (range 2,000–6,640 mGy).</p>
<p style="text-align: justify;">Conclusion Physical dosimetry and the incidence of partial epilation indicate that about one fifth of the patients submitted to NEP received radiation doses comparable to those linked to the occurrence of tumors. The potential risks of developing tumors after a long delay, when compared to the immediate benefits of endovascular treatment of aneurysm and arteriovenous malformations (AVM) of the brain, do not counterindicate NEP, but increased awareness of the risk should help physicians and patients to make a fully informed decision when other treatments are available.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3617/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Predictors of seizure freedom in the surgical treatment of supratentorial cavernous malformations</title>
		<link>http://www.neurosurgery-blog.com/archives/3568</link>
		<comments>http://www.neurosurgery-blog.com/archives/3568#comments</comments>
		<pubDate>Thu, 22 Dec 2011 23:00:26 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Epilepsy]]></category>
		<category><![CDATA[Vascular]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[Cavernoma]]></category>
		<category><![CDATA[cavernous angioma]]></category>
		<category><![CDATA[resection]]></category>
		<category><![CDATA[seizure]]></category>
		<category><![CDATA[vascular disorders]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3568</guid>
		<description><![CDATA[J Neurosurg 115:1169–1174, 2011. DOI: 10.3171/2011.7.JNS11536
Seizures are the most common presenting symptom of supratentorial cerebral cavernous malformations (CCMs) and progress to medically refractory epilepsy in 40% of patients. Predictors of seizure freedom in the resection of CCMs are incompletely understood.
Methods. The authors systematically reviewed the published literature on seizure freedom following the resection of supratentorial [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/12/cavernoma.jpg"><img class="alignleft size-thumbnail wp-image-3569" title="cavernoma" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/12/cavernoma-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 115:1169–1174, 2011. DOI: 10.3171/2011.7.JNS11536</strong></p>
<p style="text-align: justify;">Seizures are the most common presenting symptom of supratentorial cerebral cavernous malformations (CCMs) and progress to medically refractory epilepsy in 40% of patients. Predictors of seizure freedom in the resection of CCMs are incompletely understood.</p>
<p style="text-align: justify;">Methods. The authors systematically reviewed the published literature on seizure freedom following the resection of supratentorial CCMs in patients presenting with seizures. Seizure outcomes were stratified across 12 potential prognostic variables. A total of 1226 patients with supratentorial CCMs causing seizures were identified across 31 predominantly retrospective studies; 361 patients had medically refractory epilepsy.</p>
<p style="text-align: justify;">Results. Seventy-five percent of the patients were seizure free after microsurgical lesion removal, whereas 25% continued to have seizures. All patients had had preoperative seizures and &gt; 6 months of postoperative follow-up. Modifiable predictors of postoperative seizure freedom included gross-total resection (OR 36.6, 95% CI 8.5–157.5) and surgery within 1 year of symptom onset (OR 1.83, 95% CI 1.30–2.58). Additional prognostic indicators of a favorable outcome were a CCM size &lt; 1.5 cm (OR 15.4, 95% CI 5.2–45.4), the absence of multiple CCMs (OR 2.02, 95% CI 1.13–3.60), medically controlled seizures (OR 2.38, 95% CI 1.29–4.39), and the lack of secondarily generalized seizures (OR 3.33, 95% CI 2.09–5.30). Other factors, including extended resection of the hemosiderin ring, were not significantly predictive.</p>
<p style="text-align: justify;">Conclusions. In the surgical treatment of supratentorial CCMs, gross-total resection and early operative intervention may improve seizure outcome. While surgery should not be considered the first-line treatment for CCM-related epilepsy, it is important to understand the variables associated with seizure freedom in CCM resection given the considerable morbidity and diminished quality of life associated with epilepsy.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The economic impact of ventriculoperitoneal shunt failure</title>
		<link>http://www.neurosurgery-blog.com/archives/3539</link>
		<comments>http://www.neurosurgery-blog.com/archives/3539#comments</comments>
		<pubDate>Tue, 20 Dec 2011 23:00:53 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[complications]]></category>
		<category><![CDATA[hydrocephalus]]></category>
		<category><![CDATA[cost analysis]]></category>
		<category><![CDATA[pediatric hydrocephalus]]></category>
		<category><![CDATA[Ventriculoperitoneal shunt]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3539</guid>
		<description><![CDATA[J Neurosurg Pediatrics 8:539–599, 2011.DOI: 10.3171/2011.9.PEDS11192
Detailed costs to individuals with hydrocephalus and their families as well as to third-party payers have not been previously described. The purpose of this study was to determine the primary caregiver out-of-pocket expenses and the third-party payer reimbursement rate associated with a shunt failure episode.
Methods. A retrospective study of children [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/12/vpshunt2.jpg"><img class="alignleft size-thumbnail wp-image-3547" title="vpshunt" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/12/vpshunt2-113x150.jpg" alt="" width="113" height="150" /></a>J Neurosurg Pediatrics 8:539–599, 2011.DOI: 10.3171/2011.9.PEDS11192</strong></p>
<p style="text-align: justify;">Detailed costs to individuals with hydrocephalus and their families as well as to third-party payers have not been previously described. The purpose of this study was to determine the primary caregiver out-of-pocket expenses and the third-party payer reimbursement rate associated with a shunt failure episode.</p>
<p style="text-align: justify;">Methods. A retrospective study of children born between 2000 and 2005 who underwent initial ventriculoperitoneal (VP) shunt placement and who subsequently experienced a shunt failure requiring surgical intervention within 2 years of their initial shunt placement was conducted. Institutional reimbursement and demographic data from Children’s Hospital of Alabama (CHA) were augmented with a caregiver survey of any out-of pocket expenses encountered during the shunt failure episode. Institutional reimbursements and caregiver out-of-pocket expenses were then combined to provide the cost for a shunt failure episode at CHA.</p>
<p style="text-align: justify;">Results. For shunt failures, the median reimbursement total was $5008 (interquartile range [IQR] $2068– $17,984), the median caregiver out-of-pocket expenses was $419 (IQR $251–$1112), and the median total cost was $5411 (IQR $2428–$18,582). Private insurance reimbursed at a median rate of $5074 (IQR $2170–$14,852) compared with public insurance, which reimbursed at a median rate of $4800 (IQR $1876–$19,395). Caregivers with private insurance reported a median $963 (IQR $322–$1741) for out-of-pocket expenses, whereas caregivers with public insurance reported a median $391 (IQR $241–$554) for out-of-pocket expenses (p = 0.017).</p>
<p style="text-align: justify;">Conclusions. This study confirmed that private insurance reimbursed at a higher rate, and that although patients had a shorter length of stay as compared with those with public insurance, their out-of-pocket expenses associated with a shunt failure episode were greater. However, it could not be determined if the significant difference in outof- pocket expenses between those with private and those with public insurance was due directly to the cost of shunt failure. This model does not take into consideration community resources and services available to those with public insurance. These resources and services could offset the out-of-pocket burden, and therefore should be considered in future cost models.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3539/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Posterior Fossa Exploration for Trigeminal Neuralgia Patients Older Than 70 Years of Age</title>
		<link>http://www.neurosurgery-blog.com/archives/3503</link>
		<comments>http://www.neurosurgery-blog.com/archives/3503#comments</comments>
		<pubDate>Mon, 12 Dec 2011 23:00:39 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pain]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[Microvascular decompression]]></category>
		<category><![CDATA[Trigeminal neuralgia]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3503</guid>
		<description><![CDATA[Neurosurgery 69:1255–1260, 2011 DOI: 10.1227/NEU.0b013e31822ba315
Patients with medically unresponsive trigeminal neuralgia (TN) who are &#62;70 years of age often undergo operations that typically provide pain relief for &#60;5 years despite having a life expectancy that can exceed 15 years.
OBJECTIVE: To review the safety and efficacy of posterior fossa exploration (PFE) for TN patients &#62;70 years of [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/12/Posterior_Fossa_Exploration_for_Trigeminal.jpg"><img class="alignleft size-thumbnail wp-image-3508" title="Posterior_Fossa_Exploration_for_Trigeminal" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/12/Posterior_Fossa_Exploration_for_Trigeminal-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69:1255–1260, 2011 DOI: 10.1227/NEU.0b013e31822ba315</strong></p>
<p style="text-align: justify;">Patients with medically unresponsive trigeminal neuralgia (TN) who are &gt;70 years of age often undergo operations that typically provide pain relief for &lt;5 years despite having a life expectancy that can exceed 15 years.</p>
<p style="text-align: justify;">OBJECTIVE: To review the safety and efficacy of posterior fossa exploration (PFE) for TN patients &gt;70 years of age.</p>
<p style="text-align: justify;">METHODS: From 1999 to 2009, 67 TN patients &gt;70 years of age (median, 74 years) underwent a PFE. Thirty-seven patients (55%) had failed ≥1 prior surgeries (median, 2). Fifty-nine patients (88%) had a microvascular decompression, and 8 patients (12%) underwent a partial sensory rhizotomy. Follow-up (median, 40 months) was censored at the time of last contact (n = 51), additional surgery (n = 12), or death (n = 4).</p>
<p style="text-align: justify;">RESULTS: Complete pain relief (no pain, no medications) was 87% at 1 year and 78% at 5 years. Facial pain outcomes did not correlate with patient age, sex, prior surgery, or pain duration. Postoperative complications were noted in 10 patients (15%) and included ataxia (10%), hearing loss (5%), trigeminal dysesthesias (5%), facial weakness (3%), aseptic meningitis (2%), and pulmonary embolus (2%). Factors associated with postoperative complications were prior PFE (P = .01) and neurovascular compression from a dolicoectatic basilar artery (P = .03).</p>
<p style="text-align: justify;">CONCLUSION: Posterior fossa exploration is safe and effective for physiologically healthy TN patients .70 years of age. It should be deferred in older patients with TN secondary to a dolicoectatic basilar artery and patients who have persistent/recurrent pain after a previous PFE unless simpler procedures prove ineffective at controlling their facial pain.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3503/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More malfunctioning Medos Hakim programmable valves: cause for concern?</title>
		<link>http://www.neurosurgery-blog.com/archives/3459</link>
		<comments>http://www.neurosurgery-blog.com/archives/3459#comments</comments>
		<pubDate>Mon, 28 Nov 2011 23:00:44 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[complications]]></category>
		<category><![CDATA[hydrocephalus]]></category>
		<category><![CDATA[malfunction]]></category>
		<category><![CDATA[Medos Hakim programmable valve]]></category>
		<category><![CDATA[shunt]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3459</guid>
		<description><![CDATA[J Neurosurg 115:1047–1052, 2011. DOI: 10.3171/2011.5.JNS101396
In recent years, the authors have noticed a growing number of programmable valve defects at their institution. Therefore, they conducted this study to evaluate the increased incidence of malfunctioning valves.
Methods. They investigated all revisions that had been performed at their institution between 1994 and 2010 for dislodgement of the stator [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/statordislodgement.jpg"><img class="alignleft size-thumbnail wp-image-3462" title="statordislodgement" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/11/statordislodgement-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 115:1047–1052, 2011. DOI: 10.3171/2011.5.JNS101396</strong></p>
<p style="text-align: justify;">In recent years, the authors have noticed a growing number of programmable valve defects at their institution. Therefore, they conducted this study to evaluate the increased incidence of malfunctioning valves.</p>
<p style="text-align: justify;">Methods. They investigated all revisions that had been performed at their institution between 1994 and 2010 for dislodgement of the stator of a standard Medos Hakim programmable valve with a prechamber.</p>
<p style="text-align: justify;">Results. Fifteen valves were removed because of dislodged stators. The valves had been implanted between May 16, 1993, and December 27, 2002, and were explanted between February 19, 2006, and January 22, 2010. Thus, the valves had been in place for a mean period of 11 years (median 11 years, range 7–14 years). The percentage of dislodged stators was almost 3% (15 of 546 valves). Particularly noteworthy is that all malfunctioning valves were found in children who had been younger than 1 year of age at the time of implantation.</p>
<p style="text-align: justify;">Conclusions. Medos Hakim programmable valve malfunctions are rare events but should receive careful attention. When the pressure setting cannot be adjusted, a malfunction should always be suspected and radiographic imaging should be performed to assess the valve. Stator dislodgement is the most serious form of valve adjustment failure.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3459/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Management of Adult Hydrocephalus With Ventriculoperitoneal Shunts: Long-term Single- Institution Experience</title>
		<link>http://www.neurosurgery-blog.com/archives/3227</link>
		<comments>http://www.neurosurgery-blog.com/archives/3227#comments</comments>
		<pubDate>Tue, 04 Oct 2011 22:00:40 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[complications]]></category>
		<category><![CDATA[hydrocephalus]]></category>
		<category><![CDATA[Cerebrospinal fluid shunts]]></category>
		<category><![CDATA[Shunt complication]]></category>
		<category><![CDATA[Shunt failure]]></category>
		<category><![CDATA[shunt revisión]]></category>
		<category><![CDATA[Shunt surgery]]></category>
		<category><![CDATA[Ventriculoperitoneal shunting]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3227</guid>
		<description><![CDATA[Neurosurgery 69:774–781, 2011 DOI: 10.1227/NEU.0b013e31821ffa9e
Ventriculoperitoneal shunting is the most widely used neurosurgical procedure for the management of hydrocephalus.
OBJECTIVE: To evaluate our long-term single-institution experience in the management of adult hydrocephalus patients with ventriculoperitoneal shunts.
METHODS: Adult patients who underwent ventriculoperitoneal shunt placement for hydrocephalus from October 1990 to October 2009 were included. Medical charts, operative reports, [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/10/hydrocephalus.gif"><img class="alignleft size-thumbnail wp-image-3231" title="hydrocephalus" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/10/hydrocephalus-150x150.gif" alt="" width="150" height="150" /></a>Neurosurgery 69:774–781, 2011 DOI: 10.1227/NEU.0b013e31821ffa9e</strong></p>
<p style="text-align: justify;">Ventriculoperitoneal shunting is the most widely used neurosurgical procedure for the management of hydrocephalus.</p>
<p style="text-align: justify;">OBJECTIVE: To evaluate our long-term single-institution experience in the management of adult hydrocephalus patients with ventriculoperitoneal shunts.</p>
<p style="text-align: justify;">METHODS: Adult patients who underwent ventriculoperitoneal shunt placement for hydrocephalus from October 1990 to October 2009 were included. Medical charts, operative reports, imaging studies, and clinical follow-up evaluations were reviewed and analyzed retrospectively for clinical outcome in adult hydrocephalus patients.</p>
<p style="text-align: justify;">RESULTS: A total of 683 adult patients were included in the study. The most common etiologies of hydrocephalus include idiopathic (29%), tumors and cysts (20%), postcraniotomy (13%), and subarachnoid hemorrhage (13%). The overall shunt failure rate was 32%, and the majority (74%) of shunt revisions occurred within the first 6 months. The median time to first shunt revision was 9.31 months. Etiology of hydrocephalus showed a significant impact on the incidence of shunt revision/failure and on the median time to shunt revision. Similarly, the type of hydrocephalus had a significant effect on the incidence of shunt failure and the median time to shunt revision.</p>
<p style="text-align: justify;">CONCLUSION: A large proportion of patients (32%) experience shunt failure after shunt placement for hydrocephalus. Although the overall incidence of shunt revision was comparable to previously reported studies, the fact that a large proportion of adult populations with shunt placement experience shunt failure is a concern.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Thromboembolic Complications After Neuroform Stent-Assisted Treatment of Cerebral Aneurysms: The Duke Cerebrovascular Center Experience in 235 Patients With 274 Stents</title>
		<link>http://www.neurosurgery-blog.com/archives/3034</link>
		<comments>http://www.neurosurgery-blog.com/archives/3034#comments</comments>
		<pubDate>Wed, 17 Aug 2011 22:00:06 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Vascular]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[Cerebral aneurysms]]></category>
		<category><![CDATA[Neuroform stent]]></category>
		<category><![CDATA[Stent thrombosis]]></category>
		<category><![CDATA[Stent-assisted aneurysm coiling]]></category>
		<category><![CDATA[Thromboembolic complications]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3034</guid>
		<description><![CDATA[Neurosurgery 69:369–375, 2011 DOI: 10.1227/NEU.0b013e31821bc49c
The Neuroform Stent has facilitated the endovascular treatment of wide-necked cerebral aneurysms. It is unknown which factors pose risks of thromboembolic events after stent placement.
OBJECTIVE: This series is the largest single-center study reporting on the incidence of and factors influencing thromboembolic complications after Neuroform stent placement.
METHODS: A total of 235 patients [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Neuroform.jpg"><img class="alignleft size-thumbnail wp-image-3035" title="Neuroform" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Neuroform-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69:369–375, 2011 DOI: 10.1227/NEU.0b013e31821bc49c</strong></p>
<p style="text-align: justify;">The Neuroform Stent has facilitated the endovascular treatment of wide-necked cerebral aneurysms. It is unknown which factors pose risks of thromboembolic events after stent placement.</p>
<p style="text-align: justify;">OBJECTIVE: This series is the largest single-center study reporting on the incidence of and factors influencing thromboembolic complications after Neuroform stent placement.</p>
<p style="text-align: justify;">METHODS: A total of 235 patients were treated with 274 Neuroform stents. The thromboembolic event rate was determined by imaging or clinical evidence of cerebrovascular accident within 90 days of stent placement; for patients with incomplete follow-up through chart review, telephone interviews were conducted. Analyses were performed to investigate patient factors that may be associated with stroke.</p>
<p style="text-align: justify;">RESULTS: Most aneurysms were unruptured; 30 patients (12.8%) presented with acute subarachnoid hemorrhage. Twelve patients of the 224 with follow-up (5.4%, 95% confidence interval: 2.4%-8.3%) demonstrated imaging or clinical evidence of a new thromboembolic event within 90 days of stent placement. There was a 3.1% thromboembolic rate for unruptured aneurysms and a 20% rate in patients with subarachnoid bleed. Hemorrhage was significantly associated with having a thromboembolic event (P = .002). There was a trend toward an increased thromboembolic event rate for patients with hypertension (P = .07). Larger stent caliber was significantly associated with a decreased thromboembolic event rate (P = .032).</p>
<p style="text-align: justify;">CONCLUSION: Our results suggest that the thromboembolic event rate associated with Neuroform stent use is low in unruptured aneurysms. In ruptured aneurysms, the complication rate is high, possibly partly related to restricted use of antiplatelet therapy. Stent size and hypertension may be associated with the risk of stroke, but additional studies are needed to confirm their significance.</p>
<p style="text-align: justify;">KEY WORDS: Cerebral aneurysms, Neuroform stent, Stent-assisted aneurysm coiling, Stent thrombosis, Thromboembolic complications</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3034/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Safety of microvascular decompression for trigeminal neuralgia in the elderly</title>
		<link>http://www.neurosurgery-blog.com/archives/3029</link>
		<comments>http://www.neurosurgery-blog.com/archives/3029#comments</comments>
		<pubDate>Tue, 16 Aug 2011 22:00:04 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Pain]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[complication]]></category>
		<category><![CDATA[craniotomy]]></category>
		<category><![CDATA[facial pain]]></category>
		<category><![CDATA[Trigeminal neuralgia]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3029</guid>
		<description><![CDATA[J Neurosurg 115:202–209, 2011. DOI: 10.3171/2011.4.JNS101924
Microvascular decompression (MVD) offers an effective and durable treatment for patients suffering from trigeminal neuralgia (TN). Because the disorder has a tendency to occur in older persons, the risks of surgical treatment in the elderly have been a topic of recent interest. To date, evidence derived from several small retrospective [...]]]></description>
			<content:encoded><![CDATA[<p style="text-align: left;"><strong>J Neurosurg 115:202–209, 2011. DOI: 10.3171/2011.4.JNS10192<a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Age-distribution-3273-TN-patients.jpg"><img class="alignleft size-thumbnail wp-image-3030" title="Age distribution 3273 TN patients" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/08/Age-distribution-3273-TN-patients-150x150.jpg" alt="" width="150" height="150" /></a>4</strong></p>
<p style="text-align: justify;">Microvascular decompression (MVD) offers an effective and durable treatment for patients suffering from trigeminal neuralgia (TN). Because the disorder has a tendency to occur in older persons, the risks of surgical treatment in the elderly have been a topic of recent interest. To date, evidence derived from several small retrospective and a single prospective case series has suggested that age does not increase the complication rate associated with surgery. Using a large national database, the authors aimed to study the impact of age on in-hospital complications following MVD for TN.</p>
<p style="text-align: justify;">Methods. Using the Nationwide Inpatient Sample (NIS) for the 10-year period from 1999 to 2008, the authors selected all patients who underwent MVD for TN. The primary outcome of interest was the in-hospital mortality rate. Secondary outcomes of interest were cardiac, pulmonary, thromboembolic, cerebrovascular, and wound complications as well as the duration of hospital stay, total hospital charges, and discharge location. An elderly cohort of patients was first defined as those 65 years of age and older and then redefined as those 75 years and older.</p>
<p style="text-align: justify;">Results. A total of 3273 patients who underwent MVD for TN were identified, having a median age of 57 years. Within this sample, 31.5% were 65 years and older and 10.7% were 75 years and older. The in-hospital mortality rate was 0.68% for patients 65 years or older (p = 0.0087) and 1.16% for those 75 years or older (p = 0.0026). In patients younger than 65 years, the in-hospital mortality rate was 0.13% (3 deaths among 2241 patients). As analyzed using the chi-square test (for both 65 and 75 years as the age cutoff) and the Pearson rank correlation coefficient, the risk of cardiac, pulmonary, thromboembolic, and cerebrovascular complications was higher in older patients (that is, those 65 and older and those 75 and older), but the risks of wound complications and CNS infection were not. The risk of any in-hospital complication occurring in a patient 65 years and older was 7.36% (p &lt; 0.0001) and 10.0% in those 75 years and older (p &lt; 0.0001). There was no difference in the total hospital charges associated with age. The duration of the hospital stay was longer in older patients, and the likelihood of discharge home was lower in older patients.</p>
<p style="text-align: justify;">Conclusions. Microvascular decompression for TN in the elderly population remains a reasonable surgical option. However, based on data from a large national database, authors of the present study suggest that complications do tend to gradually increase in tandem with an advanced age. While age does not act as a risk factor in isolation, it may serve as a convenient surrogate for complication rates. The authors hope that this information can be of use in guiding older patients through decisions for the surgical treatment of TN.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3029/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

